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Background  Accurate and consistent risk assessment is vital in biomedical research. 
Yet, current evaluation of the risks of research interventions often does not take into 
account the relevant empirical data. This approach raises concern that current practice 
may not be protecting research subjects adequately, or that it may be blocking acceptable 
research.  
Purpose  To propose and evaluate the possibility of creating and maintaining a Research 
Risk Repository which would make empirical data on the risks of research interventions 
available to IRBs, investigators, funders, and others. 
Methods  Analysis of the usefulness of a Research Risk Repository and evaluation of 
whether currently available empirical data are sufficient to establish such a repository. 
Results  Creation of a Research Risk Repository would provide a vital resource for 
systematically and accurately evaluating the risks of clinical research. Realizing this goal 
requires data that have at least 4 characteristics: 1) trustworthy: to ensure credibility to 
all stakeholders; 2) robust: to support confident risk determinations; 3) inclusive: to 
cover all potential harms of the interventions under review; and 4) comprehensive: to 
determine which factors influence the risks of the interventions under review. Evaluation 
of existing data reveals that they satisfy these requirements for only a few research 
interventions and, even in those cases, only to a limited extent. Gaps in the currently 
available evidence highlight the need for systematic collection and maintenance of data 
on the risks posed by research interventions.  
Limitations  Creation and maintenance of a Research Risk Repository would be laborious 
and costly and require regular updating as new data are collected, and as new practices 
and interventions emerge. 
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Conclusions  A Research Risk Repository has the potential to significantly improve the 
consistency and accuracy of the evaluation of research risks. However, currently 
available data are generally insufficient for this purpose. Future collection and 
maintenance of data on the risks posed by research interventions will help to ensure that 
research subjects receive appropriate protection.  
 
318 words 
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THE ETHICS OF RESEARCH RISK AND EMPIRICAL DATA 
The ethical appropriateness of biomedical research depends on accurate and consistent 
assessment of the risks faced by research subjects. Accurate and consistent assessment of 
the risks of biomedical research in turn requires access to empirical data on the risks 
posed by research interventions. Yet, few systematic data are available on the risks of 
even common research interventions. As a result, institutional review boards (IRBs) and 
others currently evaluate the risks of biomedical research based largely on intuition alone.  
The problems with relying on intuition alone are highlighted by extensive empirical 
data from psychology, which reveal that intuitive evaluation of risks is strongly 
influenced by numerous cognitive biases (1-4). For example, people tend to judge 
familiar activities as less risky than unfamiliar ones. This bias increases the chances that 
those familiar with an intervention will judge it to be low risk, while those not familiar 
with the intervention will judge it to be higher risk.  
This concern is reinforced by empirical studies which find significant variation in the 
assessment of research risks (5-7). In a survey of 188 IRB chairpersons in the U.S., 23% 
categorized allergy skin testing as minimal risk in healthy 11-year olds, 43% categorized 
the same procedure, in the same population, as a minor increase over minimal risk, and 
27% categorized it as more than a minor increase over minimal risk (5).  
It is unlikely that the actual risks of allergy skin testing in healthy 11-year olds vary to 
this extent between sites, suggesting that the current evaluation of research risks does not 
always reflect the risks subjects face. Some may be underestimating the risks posed by 
research interventions, and thereby failing to protect participants from excessive risks. 
Others may be overestimating the risks, and thereby inadvertently blocking acceptable 
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research. Variation in risk judgments across sites also poses a significant obstacle to 
important research that must be conducted in multiple sites, such as research with 
children and research on rare diseases. 
The present paper proposes and evaluates the feasibility of establishing a Research 
Risk Repository—a centralized database that would store and make available to IRBs, 
investigators, funders, and others, systematic data on the risks of research interventions. 
Creation of a Research Risk Repository would provide the data necessary for making 
accurate and consistent risk evaluations, thus helping to better protect research 
participants from excessive risks, while promoting important research consistent with 
adequate subject protection.  
 
THE NEED FOR A RESEARCH RISK REPOSITORY 
To assess the risks of research interventions, such as lumbar puncture and allergy skin 
testing, IRBs could rely on empirical data obtained at their local institutions. This 
approach has the virtue of basing risk assessments on data that reflect local 
circumstances. However, it leaves IRBs without a way to systematically evaluate the 
risks of interventions performed at their institutions for the first time. Furthermore, while 
local risk data often are necessary for judging research risks accurately, they typically are 
not sufficient. Data from one or even several institutions often will not include enough 
data points to capture low probability events, such as the risk of anaphylactic shock from 
allergy skin testing. To capture these events, and adequately protect research subjects, 
IRBs need access to large datasets on the risks of research interventions. 
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One way to address this need would be to establish a Research Risk Repository—a 
database that maintains the available data on the outcomes of research interventions, and 
makes these data widely accessible. A Research Risk Repository would help IRBs to 
assess accurately the risks of research interventions. IRBs also could use the repository to 
identify ways to reduce risks to participants. For example, if the repository reveals that 
using a narrower needle significantly reduces the likelihood of postdural headache 
following lumbar puncture, reviewers could consider requiring investigators to use 
narrower needles. 
Investigators also could rely on the repository when writing consent forms and 
discussing research risks with potential subjects. Similarly, the dataset would allow 
quality managers to compare the outcomes for research interventions across institutions, 
and use this information to improve institutional practices. Finally, investigators, 
sponsors, and IRBs could use the repository to identify gaps in the available data and 
consider ways to collect additional data. For example, IRBs could require collection of 
more data as part of the study when the existing evidence suggests that the risks of the 
interventions being used are acceptable, but the available data are incomplete. This 
approach would allow IRBs to confirm the assumption on which they approve the study – 
namely, that the risks are acceptable. In addition, funders, such as the NIH, could identify 
gaps in the empirical data and invite investigators to collect the needed data. 
 
FOUR CRITERIA  
To provide the data needed to evaluate the risks of research accurately, a Research Risk 
Repository would need to satisfy at least four criteria.  
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The data in the repository should be trustworthy to the various stakeholders in research. 
Perhaps the best way to promote trust would be for the repository to be operated by an 
independent non-profit organization. The work of this organization could be overseen by 
a committee of experts. A searchable online version of the repository would help to 
increase accessibility and promote accountability and trustworthiness. To avoid 
discouraging institutions from contributing their data to the repository, the online version 
could anonymize the origins of the data. 
 
The evidence should be sufficiently robust and up to date to support confident risk 
determinations. The data in the repository should capture as many observations as 
possible, made in diverse settings. The available data also should be updated as new data 
are collected. This is particularly important when techniques change in ways that likely 
influence their risks, such as the introduction of narrower needles for lumbar puncture or 
CT scanning techniques using increased levels of radiation.  
 
The data in the repository should include the types and magnitudes of all relevant 
potential harms. To protect research subjects from excessive risks, IRBs should evaluate 
all the potential physical, psychological, social, and economic harms posed by research 
interventions. This view differs from some commentators who argue that potential 
negligible harms, such as the chance of local itching as the result of an allergy skin test, 
constitute mere inconveniences – not risks – and thus can be excluded from risk 
evaluations (8). However, potential harms that are negligible on their own can have 
  8 
additive or synergistic effects. To address this possibility, a Research Risk Repository 
should include data on the types and magnitudes of all potential research harms.  
 
The data should include information on which factors influence the risks of research 
interventions. The risks posed by some interventions vary depending on the 
circumstances: how the intervention is performed (e.g., the risk of postdural puncture 
headache after lumbar puncture increases with larger needles) or who undergoes it (e.g., 
the risks of sedation increase with underlying disease). IRBs should base their risk 
determinations on data relevant to the research under review. A Research Risk 
Repository could facilitate these determinations by stratifying the data by relevant 
contextual factors, tailored to individual interventions. For example, the repository could 
classify the needle size used for lumbar puncture as small (24-27 G), medium (20-22 G), 
or large (16-19 G). Similarly, where relevant, it will be important to specify the extent to 
which interventions pose greater or lower risks in specific populations, such as children. 
 
EVALUATION OF FEASIBILITY 
Review of Existing Risk Data 
The most straightforward way to create a Research Risk Repository would be simply to 
collect and collate existing empirical data on the risks of research interventions. To 
maximize its usefulness, the repository should focus, at least initially, on common 
research interventions that are used in contexts which do not offer participants the 
potential for clinical benefit, such as biopsies or blood draws performed for purely 
research purposes. Research interventions that pose risks to subjects without a 
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compensating potential for clinical benefit raise the greatest ethical concern. Moreover, 
whether the risks of these “non-beneficial” interventions are classified as “minimal” or 
greater than “minimal” has important practical implications. For example, most current 
guidelines and regulations allow “non-beneficial” interventions to be performed in 
healthy children only when they pose minimal risk. 
To evaluate whether existing data satisfy the four requirements of a Research Risk 
Repository, we conducted a preliminary literature search on the risks of common research 
interventions (figure). To be included in the search, the interventions had to meet the 
following criteria: 1) performed routinely in the research setting; 2) often performed for 
research purposes only (and sometimes controversial in this “non-therapeutic” context); 
and 3) sufficient data are likely available on the risks posed by the intervention.  
We started by classifying research interventions in 10 categories: 1) asking questions 
(e.g., survey of health-related behaviors); 2) physical examination (e.g. blood pressure 
measurement); 3) imaging (e.g., ultrasound, CT scan); 4) measuring electrical activity 
(e.g., ECG, EEG); 5) sampling fluids or cells (e.g., blood draw, apheresis); 6) removing 
tissue (e.g. skin or muscle biopsy); 7) instilling substances (e.g. allergy skin testing); 8) 
genetic testing (e.g. genetic test on previously obtained sample); 9) hospitalization (e.g. 
overnight stay in hospital); 10) record keeping (e.g. record confidential medical 
information). In consultation with 25-30 clinical or biomedical researchers, IRB 
members, and experts in research ethics, we drafted a list of 33 research interventions that 
met the first two inclusion criteria (table 1). We then performed brief literature searches 
to determine whether the existing data were likely to satisfy the third inclusion criterion 
of including sufficient data points on the risks of the 33 interventions.  
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This process, together with consultation with our group of experts, led to the 
exclusion of sixteen interventions for which sufficient data were unlikely to be available. 
For example, we could not identify pertinent data on repeat blood sampling, defined as a 
series of 5-10 and 10-20 blood draws of a maximum of 10 cc each. Although some 
studies record the volume of diagnostic blood loss in the inpatient setting, they often do 
not estimate the clinical impact. Analogies to blood donation are weak because the data 
on the risk of anemia and iron depletion in this setting are scarce and/or outdated (9). 
Similarly, the clinical implications of exposure to low dose radiation remain unclear (10). 
We thus excluded imaging interventions involving radiation, such as X-rays and CT 
scans.  
To identify the highest quality datasets for the remaining 17 interventions (see 
appendix 1), we retrieved citations from PubMed combining the MeSH term for the given 
research intervention (e.g. “skin tests” for allergy skin test) with MeSH terms for risk 
(e.g. risk OR adverse effects), and included all studies published in English on or before 
10 January 2009 (see table 2 for search strategy). The first author (AR) then contacted an 
independent clinical expert/researcher with the results. One expert per procedure was 
contacted. Only two of the consulted experts worked outside of NIH at the time. The 
experts helped to select the highest quality references and identified important papers or 
book chapters that were not retrieved by the search, often in consultation with their 
colleagues.  
The first author (AR) or a research assistant catalogued the retrieved risk data for each 
intervention in a table (see table 3 for the template table), arranging potential physical 
harms and associated likelihoods (given per 100,000) according to body systems. 
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Potential psychological and social or economic harms were listed separately, if available. 
Data that included pediatric populations were shaded in grey. Each table also indicates 
the total number of observations in the cited studies (i.e. the total number of interventions 
performed or the number of observed cases in the context of case reports), and provides 
relevant information about the respective study contexts. A 95% Confidence Interval 
(95% CI) for proportions was calculated using the Wilson formula (“Wilson score 
interval” (11)). The analysis was performed with open source software of the “R 
foundation for statistical computing” (http://www.r-project.org/).  
The identified clinical experts/researchers provided the first author (AR) with a detailed 
description of the potential harms resulting from the given research intervention, 
including the type, duration, and reversibility of each potential harm. The experts also 
provided likelihood estimates for potential harms not provided in the literature, as well as 
general comments on the quality of the data obtained and relevant background 
information on the given intervention (online appendix 1). Finally, the experts helped to 
develop “summary tables” for each intervention (online appendix 2). With the exception 
of the table on moderate sedation for children, the summary tables do not reflect data 
collected in pediatric populations. 
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Figure. Process used to test the feasibility of creating a Research Risk Repository.  
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Table 1. Research interventions included in the preliminary review of the existing 
data (listed in alphabetical order). The tables listing the data of each intervention, as well 
as summary tables developed in consultation with experts, are available as in the online 
appendix. With the exception of the table for moderate sedation in children, the summary 
tables do not reflect data collected in pediatric populations. 
 
Allergy skin test (epicutaneous) 
Apheresis 
Blood draw (single) 
Bone marrow biopsy 
Bronchoscopy 
Cardiac stress test (pharmacological)  
Electrocardiogram (ECG) 
Electroencephalogram (EEG) 
Gadolineum-based contrast agent 
Intravenous catheter (peripheral) 
Intravenous glucose tolerance test (peripheral) 
Liver biopsy (percutaneous) 
Lumbar puncture 
Lymph node biopsy (axillary or inguinal) 
Magnetic Resonance Imaging (MRI) 
Sedation (moderate, i.e. with purposeful response to verbal or tactile stimulation) 
Skin biopsy (“punch” biopsy) 
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Table 2. PubMed Search Strategy. 
 
MeSH term for research interventions (e.g. “skin tests” for allergy skin test) 
          AND 
Risk [MeSH] or adverse effects [MeSH] or mortality [MeSH] or incidental findings 
[MeSH] or (adverse effects AND psychology) [MeSH] or stress, psychological 
[MeSH] or adaptation, psychological [MeSH] or socioeconomic factors [MeSH] 
or stereotyping [MeSH] 
 AND 
English only 
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Table 3. Template table used to extract the available risk data. Rows reporting data from pediatric populations were shaded in 
grey. Notes on the quality of the data and background information about the procedure, as well as the list of references, were recorded 
at the bottom of each table.  
 
[Name of Intervention]: Risks and Complications 
 
Harm Likelihood (per 100,000) 
95% CI 
(per 100,000) N Study Context Ref. 
1. Physical Harm      
a. Morbidity      
General symptoms:      
E.g. Malaise      
Neurological System:      
E.g. Headache      
Cardiovascular System:      
E.g. Syncope      
Respiratory System:      
E.g. Wheezing      
Gastro-intestinal System:      
E.g. Nausea and Vomiting      
Kidney and urinary tract:      
E.g. Cystitis      
Reproductive System:      
E.g. Prostatitis      
Immune System and Blood:      
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E.g. Systemic Allergic Reaction      
Loco-motor System:      
E.g. Arthritis      
Skin:      
E.g. Contact Dermatitis      
Head, Eye, ENT:      
E.g. Hearing loss      
b. Mortality      
Death      
2. Psychological Harm      
E.g. Anxiety      
3. Socio-Economic Harm      
E.g. Job loss      
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Results of the Review 
The review yielded empirical data on the risks of the 17 included interventions. The 
searches retrieved from about 3 to 35 references per intervention that the clinical 
experts/researchers judged to be of sufficient quality to support risk determinations. The 
number of observations in the individual datasets ranged from 50 to several 100,000. For 
several interventions, including ECG and EEG, the search identified case reports only.  
The reviewed literature used a wide range of approaches to evaluate risks. The two 
dominant approaches were 1) retrospective analysis of existing data, for example from 
existing medical or research records, and 2) surveys that ask members of professional 
societies to report on the incidence of adverse events for a given procedure and time 
interval. Other methods included prospective studies, case reports, review papers, and 
published expert opinion. The available data often varied in the types of potential harms 
that were reported for each intervention, and how these potential harms were defined. 
Some of the reported likelihoods for a given potential harm also varied considerably. In 
some cases, the reported upper likelihood differed from the reported lower likelihood by 
a factor of 20-30 (online appendix 1 and 2). 
Table 4 offers a sample table of the available data on epicutaenous allergy skin 
testing.   
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Table 4. Risks of epicutaneous allergy skin testing (sample table).  
Allergy Skin Test (Epicutaneous): Risks and Complications 
 
Harm Likelihood (per 100,000) 
95% CI 
(per 100,000) N Study Context Ref. 
1. Physical Harm      
a. Morbidity      
Neurological System:      
Pain, similar to or less than pain from 
blood draw ~100,000 N/A N/A Expert opinion N/A 
Immune System and Blood:      
Systemic allergic reaction, involving 
pruritus, flushing, light-headedness, 
urticaria, angioedema, asthmatic or 
hay fever symptoms 
15-23 4-55,  9-67 13,218 
Patients at the Mayo Clinic (1992-97) with on 
average 27 pricks per person; limited to 
respiratory allergy tests; includes children  
(12) 
Systemic allergic reaction 19 5-70 10,400 
Patients in private practice (1976-1989); 
includes both epicutaneous and intradermal 
allergy tests; includes children 
(13) 
Systemic allergic reaction 20 7-57 16,204 Epicutaneous tests (all kinds of allergies) in healthy volunteers (1976-1980) (14) 
Systemic allergic reaction 30 13-71 16,505 
Patients at the Mayo Clinic (1992-97) with on 
average 27 pricks per person; all kinds of 
allergy tested; includes children  
(12) 
Systematic allergic reaction 351 137-900 1,138 
Patients with diagnosed food allergy 
undergoing food allergy skin tests (on average 
30 pricks per person); includes children 
(15) 
Systemic allergic reaction 521 239-1,132 1,152 Percutaneous tests (all kinds) in 1,152 children  (16) 
Systemic allergic reaction 6,522 5,236-8,097 1,152 Percutaneous tests (all kinds)  in 1,152 (16) 
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children <6 months 
Mild systemic allergic reaction, 
involving self-limiting hay fever 
symptoms, urticaria requiring 
antihistamine treatment 
~13-26 N/A N/A Expert opinion N/A 
Moderate to severe systemic allergic 
reaction, involving asthmatic 
symptoms and drop in blood pressure, 
requiring subcutaneous epinephrine 
treatment ± intubation 
 
~2-5 N/A N/A 
 
Expert opinion N/A 
Skin:      
Local allergic reaction with intensive, 
transient pruritus (5-15 min) ~50,000 N/A N/A Expert opinion N/A 
b. Mortality      
Death 0 0-24 16,204 Percutaneous tests (all kinds) in 16,204 healthy volunteers (1976-1980) (14) 
Death 0 0-23 16,505 Patients evaluated for allergic diseases at the Mayo Clinic (1992-97); includes children  (12) 
Death 0 0-36 10,400 
Patients in private practice (1976-1989); 
includes both epicutaneous and intradermal 
allergy tests; includes children 
(13) 
Death 0 N/A N/A 
Fatalities as reported by American Academy of 
Allergy and Immunology (AAAI) members; 
all skin tests (not only epicutaneous) 
performed between 1985-89 
(17) 
Death Case report N/A 1 
Fatalities as reported by AAAI members 
(response rate 25%) representing 646 
institutions; all epicutaneous skin tests 
performed between 1990-2001; death from 
anaphylactic shock in asthmatic patient 
(18) 
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undergoing 90 food prick tests (implausibly 
high number of tested allergens); “To our 
knowledge, this is the first report of a fatality 
associated exclusively with epicutaneous 
testing” 
Death Case report N/A 6 
Fatalities as reported by American Academy of 
Allergy and Immunology (AAAI) members; 
all skin tests (not only epicutaneous) 
performed between 1959-84 
(19) 
 
Quality of data 
 
- Retrospective data analysis (12, 13), physician surveys (17-19), prospective study (13) 
- Review articles (20, 21) 
- Data include pediatric patients without specifying risks for children; only specific pediatric data (16) 
- Incidence of adverse events is probably too high: studies do not have placebo control arms, so it is possible that random 
allergic reaction coincided with allergy skin testing (evidence for this in (12)) 
 
Background information 
 
- Each epictuaneous skin test involves on average 15-30 pricks per patient (testing the same number of allergens) 
- Pain from superficial skin prick is less than pain from blood draw 
- Local reaction involves intense pruritus for about 10-15 min 
- Systemic reaction 
o ~85% mild reaction: self-limiting hay fever symptoms involving sneezing, runny nose and itching eyes for ~1h, 
urticaria with recovery under antihistamine treatment in ≤1h 
o ~15% moderate to severe reaction: asthmatic symptoms, hypotension, requires epinephrine treatment 
- Anaphylactic shock: essentially no risk due to monitoring and early intervention 
o For comparison: risk of anaphylactic shock in immunotherapy is 1 per 2-2.5 million injections (17) 
- ~85% of research focuses on inhaled allergens (asthma studies), ~15% focus on food allergens
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Do Existing Data Meet the 4 Criteria for a Research Risk Repository? 
While our search was not relevant to determining whether the obtained data would be 
regarded as trustworthy by relevant stakeholders (Criterion #1), it does provide evidence 
on the extent to which the available data meet the other three criteria (see online appendix 
1 for evidence supporting the examples used in this section).   
 
Criterion #2: Are the available data sufficiently robust and up to date? Based on expert 
opinion, we included only those research interventions in the search that were expected to 
yield sufficient risk data. Even so, the quality of the available risk data varied greatly. We 
found essentially no data on interventions generally perceived to be low risk. For 
example, our search identified only three studies on the risks of i.v. glucose tolerance 
testing, and one paper that cites some data as a personal communication. While this 
finding may reflect the fact that serious harms from glucose tolerance testing are unlikely 
to occur, the repository needs to clearly distinguish an absence of systematic data on risks 
from systematic data pointing to an absence of risks for a given intervention. 
In addition, the data often were based on low numbers of observations, which is also 
reflected in large confidence intervals. This shortcoming likely will be difficult to 
overcome by summarizing data from existing datasets due to a surprising lack of 
common definitions for potential harms or adverse events. Some datasets did not provide 
any definitions of the reported adverse events. In other cases, the different datasets used 
conflicting definitions. For example, i.v. catheters pose a risk of phlebitis. But, some 
studies defined phlebitis as the occurrence of any local symptoms, such as redness, 
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swelling, local heat, tenderness, or a palpable venous cord. Other studies defined phlebitis 
as requiring the presence of two, sometimes three, of these symptoms. 
Finally, some of the available risk data reflect outdated practices. For example, the 
largest available datasets on the risks of percutaneous liver biopsy were collected in the 
1970s/80s when the biopsies were done without ultrasound guidance, typically by general 
internists without specialist training.  
 
Criterion #3: Do the existing data include the types and magnitudes of all potential 
harms? The available data focus primarily on the physical risks of the different 
interventions. Data on psychological risks are scarce, and data on any social or economic 
risks are virtually non-existent. Similarly, data on potential negligible harms, such as the 
dizziness that most people experience when undergoing an i.v. glucose tolerance test, are 
rarely recorded and their likelihood had to be estimated by expert opinion. This makes it 
difficult to evaluate the magnitude and likelihood of these harms, important steps in 
evaluating research risks systematically (42). 
 
Criterion #4: Do the available data cover contextual factors that influence risks? 
Information on contextual factors – how the intervention is performed, who undergoes it, 
and who performs it – is often incomplete. For example, although the risks of sedation 
are significantly influenced by underlying disease, the available data rarely include subset 
analyses based on the American Society of Anesthesiology (ASA) physical status 
classification. In addition, there are almost no data on the risks of common research 
interventions in relevant subpopulations, such as children and pregnant women. For 
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example, moderate sedation was the only intervention for which we could develop a 
summary table specifically for children. This limitation precludes the possibility of 
making useful estimates about the variance of risks across research sites. Such estimates 
are helpful for local IRBs only to the extent that they are linked to contextual information 
about local practices and specific populations. 
The available data were almost exclusively collected in the clinical context. Because 
risk data specifically from the research context are largely absent, it is difficult to assess 
to what extent this finding confounds the available evidence. Recorded risks might be 
lower in the research setting because research institutions often have more staff, are better 
equipped, and typically have a higher level of safety monitoring. In addition, the clinical 
context can introduce confounding factors that might increase risks. For example, the 
available data on the risks of lymph node biopsy were collected primarily in oncology 
patients who underwent sentinel lymph node biopsies. These biopsies tend to be deeper 
than research biopsies and thus run a higher risk of nerve injury than they would in 
healthy research subjects. 
 
IMPLICATIONS 
The Need to Collect More Data  
The conclusion that existing risk data are not sufficiently robust, inclusive, and 
comprehensive raises additional concern that current evaluations of research risks, even 
when they appeal to the available data, may not accurately reflects the risks actually 
faced by research participants. This finding provides compelling support for establishing 
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a Research Risk Repository. Our literature search also offers several lessons pertinent to 
collecting the data necessary to establish such a repository.  
First, significant additional data are needed on a number of common research 
interventions. To adequately reflect current practice, these data should be collected in 
multiple institutions and settings. Second, common definitions of adverse events, as well 
as coding systems to classify different practices and settings, need to be developed for 
most research interventions. Third, a Research Risk Repository is likely to be limited to 
interventions for which standard practices are recognized. It is impossible to collate data 
when there are no standard practices, or when standard practice varies widely, as 
currently is the case with moderate sedation and several other interventions (online 
appendixes).  
 
Present Uses of the Available Risk Data 
Creating a Research Risk Repository is likely to take a significant amount of time. Given 
the pressing need to improve risk judgments, reviewers can cautiously consider the 
results of our preliminary literature search when they assess the risks of research 
interventions. When doing so, IRBs need to carefully judge both the quality of the data 
and their relevance for the study under review. Notably, the strength of the data varies for 
the different interventions from very weak to very strong. For example, the literature on 
gadolineum-based contrast agents, which are used during imaging interventions, includes 
datasets with hundreds of thousands of observations. Recognizing that these data are 
lacking in detail and contextual factors, they are overall robust, and thus merit serious 
consideration (online appendixes). When estimates about the likelihood of particular 
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harms vary, IRBs should carefully consider the confidence interval for the likelihood 
point estimates, generally erring on the side of caution and giving more weight to higher 
likelihood estimates. IRBs also need to judge, based on the limited information available 
on contextual factors, to what extent the available data apply to local conditions. When 
the institutional setting and practices or the study population differ significantly from the 
existing evidence, IRBs should ask investigators to provide their own data. 
 
ESTABLISHING AND MAINTAINING A RESEARCH RISK REPOSITORY 
Creation of a Research Risk Repository should proceed in several steps. First, an 
appropriate source of funding will have to be identified. To promote the trust of all 
stakeholders in research, funding should probably be public (e.g., from NIH and/or the 
FDA). Second, an interdisciplinary committee of experts that oversees the repository will 
be needed. The committee could be charged with making initial decisions about the 
repository, in particular which research interventions to focus on first. Third, 
interdisciplinary groups will be needed to systematically review existing data on the 
identified interventions, using established methods, such as those developed by the 
Cochrane Collaboration (43). This effort could be extended by a call for investigators to 
submit unpublished data.  
Fourth, based on this work, the committee of experts should develop common 
definitions of adverse events and potential harms where necessary. It would also be 
useful to define standard practices for each intervention and develop codes for these 
practices, as well as codes for relevant characteristics of research institutions (e.g., 
number of staff, training institution). Fifth, in parallel to these efforts, a team of 
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statisticians and database managers could develop the basic structure and functions of the 
database. This team could start by collating and analyzing the published data with those 
newly submitted by investigators, drawing on established methods for metaanalysis, 
while preparing a mechanism for ongoing data collection and analysis.  
Data could be transferred from the research institutions to a centralized database by 
means of a computer program that allows investigators or other research staff to directly 
export their data to the Research Risk Repository, limiting the effort needed specifically 
to complete this task. Sixth, it might make sense to start data collection at large centers, 
such as NIH or the Mayo Clinic, and to evaluate the experience there before 
progressively expanding the effort. Finally, to ensure the Research Risk Repository 
provides up to date information, it should be maintained and updated on a regular basis.  
 
LIMITATIONS AND CHALLENGES 
An inherent limitation of a Research Risk Repository is that it requires updating as novel 
research interventions emerge. Creation and maintenance of a Research Risk Repository 
will also be laborious and costly. However, the costs and effort of establishing a 
repository would probably not exceed the range for a larger research project with a 
budget of several million dollars. The continuous costs of maintenance and 
administration should be dramatically lower. While the total costs of a Research Risk 
Repository would be significant, they should be evaluated within the larger context of 
public research expenditures of more than $30 billion per year in the U.S. alone (44). 
Several million dollars seem to be a reasonable investment to protect research 
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participants from excessive risks, while promoting important research consistent with 
adequate subject protection.  
Another challenge is to achieve trust in the Research Risk Repository by the various 
stakeholders in research. To achieve this, it is important that the repository be operated by 
an independent non-profit organization, overseen by a committee of independent experts, 
and made publicly available (e.g., as an online version that people could use to research 
the risks of common research interventions). Creation of a low-threshold mechanism for 
complaints about the repository should also help to foster trust. 
 
CONCLUSION 
IRBs are charged with evaluating the risks of research interventions. To ensure that 
participants are protected from excessive risks, and acceptable research is allowed to 
proceed, it is vital that these judgments reflect the actual risks posed by research 
interventions. However, IRBs vary greatly in how they classify the risks of research 
interventions. This variation traces, at least in part, to the fact that few systematic data are 
available on the risks of research interventions; IRBs consequently evaluate research 
risks without access to the relevant empirical data.  
The present analysis suggests that establishing a Research Risk Repository – a 
centralized database that maintains systematic data on the outcomes of research 
interventions – would offer an effective solution to this concern. A preliminary literature 
search suggests that existing risk data are insufficient for creating such a repository, 
revealing the need for mechanisms to systematically collect data on the risks of research 
interventions. In the interim, IRBs might cautiously consider the existing data collated 
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here when evaluating research risks, provided they are cognizant of their many 
limitations. 
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